Glass House Brands (GLAS) Research & Development (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Research & Development of $529000.0 for Q1 2026, up 11.13% quarter-over-quarter from $476000.0 in Q4 2025.
Glass House Brands (GLAS) Research & Development (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Research & Development for 7 consecutive years, with $529000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development changed N/A year-over-year to $529000.0; the TTM figure through Mar 2026 stood at $2.5 million (changed N/A YoY), while the FY2025 annual figure was $2.7 million, up 10.38% from the prior year.
- Research & Development rose to $529000.0 in Q1 2026 per GLAS's latest filing, from $476000.0 in the prior quarter.
- Across five years, Research & Development topped out at $997000.0 in Q2 2023 and bottomed at $476000.0 in Q4 2025.
- Historically, Research & Development has averaged $761711.6 across 5 years, with a median of $803678.0 in 2022.
- Annual changes were most pronounced in 2022 — Research & Development jumped 77.22% — and 2024, when it plunged 31.59%.
- Glass House Brands' Research & Development stood at $859000.0 in 2022, then climbed by 16.07% to $997000.0 in 2023, then slumped by 31.59% to $682000.0 in 2024, then tumbled by 30.21% to $476000.0 in 2025, then advanced by 11.13% to $529000.0 in 2026.
- Business Quant data shows GLAS's Research & Development at $529000.0 in Q1 2026, $476000.0 in Q4 2025, and $703000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Glass House Brands | 835.49 Mn | 816.93 Mn | 15.77 Mn | 357,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 529,000.00 |
| Dec 31, 2025 | 476,000.00 |
| Sep 30, 2025 | 703,000.00 |
| Jun 30, 2025 | 803,000.00 |
| Jun 30, 2024 | 682,000.00 |
| Jun 30, 2023 | 997,000.00 |
| Dec 31, 2022 | 859,000.00 |
| Sep 30, 2022 | 804,356.00 |
| Jun 30, 2022 | 898,000.00 |
| Mar 31, 2022 | 865,760.00 |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 1.01 Mn |
| Mar 31, 2021 | 488,535.00 |
| Dec 31, 2020 | 371.35 Bn |
| Sep 30, 2020 | 336,730.00 |
| Mar 31, 2020 | 354,425.00 |